BIOCON.BOBIOCON.BOBSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -3.35% | +12.76% | +14.83% | +18.72% | +9.20% |
| Gross Profit Growth | -9.54% | +11.60% | +12.74% | +12.78% | -39.22% |
| EBITDA Growth | -9.98% | +17.83% | +15.70% | +35.15% | +17.89% |
| Operating Income Growth | -18.01% | +0.00% | +14.11% | -76.97% | -80.59% |
| Net Income Growth | -96.20% | +154.24% | -95.24% | +0.00% | +472.91% |
| EPS Growth | -96.18% | +154.87% | -95.26% | +0.00% | +414.29% |
| EPS Diluted Growth | -96.18% | +153.98% | -95.26% | +0.00% | +409.52% |
| Weighted Average Shares Growth | -0.45% | -0.02% | +0.59% | +4.02% | +11.86% |
| Weighted Average Shares Diluted Growth | -0.45% | -0.02% | +0.59% | +5.62% | +12.44% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +36.06% | -10.93% | +3.73% | -9.95% | -3.80% |
| Inventory Growth | +0.58% | -0.26% | +14.27% | +16.35% | +16.51% |
| Asset Growth | +4.47% | +4.86% | +10.28% | +9.86% | +9.55% |
| Book Value per Share Growth | +10.02% | +9.43% | +25.46% | +22.74% | +12.67% |
| Debt Growth | +8.26% | +12.81% | +0.28% | -1.40% | +1.04% |
| R&D Expense Growth | +2523.08% | -8.89% | +7.79% | -129.73% | +630.21% |
| SG&A Expenses Growth | +9.36% | +25.22% | +10.29% | -100.00% | +17.87% |